Scientists in Germany say they've developed a nasal vaccine that can effectively shut down Covid-19 infections in the nose and throat. In hamster studies, two doses of the weakened but live coronavirus showed "sterilizing immunity," meaning the virus couldn't replicate itself in the animals' upper airways.
This approach is promising because it aims to boost mucosal immunity, which targets the tissues that line the upper respiratory tract where the virus enters the body. Researchers hope this vaccine can prevent infections before they even occur and reduce the spread of Covid-19.
The nasal vaccine takes a new approach by manipulating the genetic material in the virus to make it harder for cells to translate. This technique, called codon pair deoptimization, is similar to how some flu vaccines are developed.
In hamster studies, the vaccine performed better than other Covid-19 vaccines, including an mRNA-based vaccine and one that uses adenovirus to deliver the instructions into cells. The researchers believe this live but weakened vaccine worked well because it closely mimics a natural infection.
However, caution is warranted, as the vaccine still needs to pass more tests before it's ready for human use. Other nasal vaccines are also in development, with several already reaching late-stage testing in humans.
Despite progress being made, researchers say that developing a pan-coronavirus vaccine that induces mucosal immunity and is long-lived remains a priority. The current vaccines may boost what's already present in the immune system, making them less effective for adults.
Live attenuated viruses have shown promise in other areas of vaccination, such as measles, mumps, and rubella. However, these vaccines can't be taken by everyone due to concerns over weakened viruses being risky for people with compromised immunity.
The German team is eagerly awaiting results from another nasal vaccine being developed by Codagenix, which uses a similar approach but has not yet been tested in humans.
This approach is promising because it aims to boost mucosal immunity, which targets the tissues that line the upper respiratory tract where the virus enters the body. Researchers hope this vaccine can prevent infections before they even occur and reduce the spread of Covid-19.
The nasal vaccine takes a new approach by manipulating the genetic material in the virus to make it harder for cells to translate. This technique, called codon pair deoptimization, is similar to how some flu vaccines are developed.
In hamster studies, the vaccine performed better than other Covid-19 vaccines, including an mRNA-based vaccine and one that uses adenovirus to deliver the instructions into cells. The researchers believe this live but weakened vaccine worked well because it closely mimics a natural infection.
However, caution is warranted, as the vaccine still needs to pass more tests before it's ready for human use. Other nasal vaccines are also in development, with several already reaching late-stage testing in humans.
Despite progress being made, researchers say that developing a pan-coronavirus vaccine that induces mucosal immunity and is long-lived remains a priority. The current vaccines may boost what's already present in the immune system, making them less effective for adults.
Live attenuated viruses have shown promise in other areas of vaccination, such as measles, mumps, and rubella. However, these vaccines can't be taken by everyone due to concerns over weakened viruses being risky for people with compromised immunity.
The German team is eagerly awaiting results from another nasal vaccine being developed by Codagenix, which uses a similar approach but has not yet been tested in humans.